Link between Homocysteine and Cardiovascular Diseases

被引：1
作者：
Obradovic M. [1 ]
Zaric B.L. [1 ]
Haidara M.A. [2 ]
Isenovic E.R. [1 ]
机构：
[1] Institute of Nuclear Sciences Vinca, University of Belgrade, Laboratory of Radiobiology and Molecular Genetics, P.O. Box 522, Belgrade
[2] Department of Physiology, College of Medicine, King Khalid University, Abha
来源：
Current Pharmacology Reports | 2018年 / 4卷 / 1期
关键词：
Atherosclerosis; Cardiovascular diseases; Homocysteine; Hyperhomocysteinemia;
D O I：
10.1007/s40495-017-0119-9
中图分类号：
学科分类号：
摘要：
Purpose of Review: Numerous studies have shown a positive correlation between serum Hcy level and various pathological conditions such as coronary, carotid, and peripheral vascular disease. Increased plasma Hcy levels are associated not only with an increased risk of arteriosclerosis but also with atherosclerosis and thrombosis. The aim of this review is to review biochemical mechanisms responsible for development and progression of cardiovascular diseases (CVD). Recent Findings: A recent finding shows that cardiac tissue function improves in hyperhomocysteinemic (HHcy) patients after consumption of folic acid and cobalamin. Furthermore, in patients with HHcy plasma levels of nitric oxide (NO) and tetrahydrobiopterin were remarkably decreased compared with the normal individuals. Cardiac endothelial function and coronary flow velocity reserve were significantly disrupted in chronic HHcy patients compared with the control subjects. Summary: Lowering elevated level of Hcy by supplementation with folic acid and B12 vitamin reduces plasma level of Hcy and substantially reduces the risk of CVD. The combination of consuming supplements of B12, B6, and folate on a daily basis reduces the progression of atherosclerosis, measured by the area of the carotid artery plaques and their administration, improve CVD and may slightly prevent the incidence of atherosclerotic vascular events. A correlation between Hcy and hypertension indicates that Hcy levels could be used as a potential marker for atherosclerosis progression. © 2017, Springer International Publishing AG, part of Springer Nature.
引用
收藏
页码：1 / 9
页数：8
相关论文
共 101 条
  • [1] Jakubowski H., Homocysteine is a protein amino acid in humans. Implications for homocysteine-linked disease, J Biol Chem, 277, 34, pp. 30425-30428, (2002)
  • [2] Fanapour P.C., Yug B., Kochar M.S., Hyperhomocysteinemia: an additional cardiovascular risk factor, Wmj, 98, 8, pp. 51-54, (1999)
  • [3] Stanger O., Et al., Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases, Z Kardiol, 93, 6, pp. 439-453, (2004)
  • [4] Brattstrom L., Et al., Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors, Eur J Clin Investig, 22, 3, pp. 214-221, (1992)
  • [5] Han L., Et al., Homocysteine, ischemic stroke, and coronary heart disease in hypertensive patients: a population-based, prospective cohort study, Stroke, 46, 7, pp. 1777-1786, (2015)
  • [6] Ferechide D., Radulescu D., Hyperhomocysteinemia in renal diseases, J Med Life, 2, 1, pp. 53-59, (2009)
  • [7] Cattaneo M., Hyperhomocysteinemia: a risk factor for arterial and venous thrombotic disease, Int J Clin Lab Res, 27, 3, pp. 139-144, (1997)
  • [8] Blum A., Et al., Homocysteine levels in patients with risk factors for atherosclerosis, Clin Cardiol, 24, 6, pp. 463-466, (2001)
  • [9] Mercie P., Et al., Homocysteine-thiolactone induces caspase-independent vascular endothelial cell death with apoptotic features, Apoptosis, 5, 5, pp. 403-411, (2000)
  • [10] Lai W.K., Kan M.Y., Homocysteine-induced endothelial dysfunction, Ann Nutr Metab, 67, 1, pp. 1-12, (2015)
12345678910